Adverse Drug Events Associated with sitagliptin Versus canagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Comparison Through a Meta-Analysis
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes Therapy"
DOI: 10.1007/s13300-018-0481-6
Abstract: IntroductionIn this meta-analysis, we aimed to systematically compare the adverse drug events associated with sitagliptin (100 mg) versus canagliflozin 100 or 300 mg in patients who were treated for type 2 diabetes mellitus (T2DM).MethodsOnline databases were searched… read more here.
Keywords: canagliflozin; versus canagliflozin; drug; drug events ... See more keywords